Search

Your search keyword '"Cupissol, D"' showing total 419 results
Start Over Author "Cupissol, D"
419 results on '"Cupissol, D"'

101. Time to secondary resistance (TSR) after interruption of imatinib (IM) in advanced GIST: Updated results of the prospective French Sarcoma Group randomized phase III trial on long-term survival.

Author

Le Cesne, A., primary, Ray-Coquard, I. L., additional, Bui Nguyen, B., additional, Adenis, A., additional, Rios, M., additional, Bertucci, F., additional, Duffaud, F., additional, Cupissol, D., additional, Chevreau, C., additional, Bompas, E., additional, Cioffi, A., additional, Chabaud, S., additional, Perol, D., additional, and Blay, J., additional

Published
2011
Full Text
View/download PDF

102. Who are the long responders to imatinib (IM) in patients with advanced GIST? Results of the BFR14 prospective French Sarcoma Group randomized phase III trial.

Author

Blesius, A., primary, Cassier, P. A., additional, Ray-Coquard, I. L., additional, Italiano, A., additional, Adenis, A., additional, Rios, M., additional, Bertucci, F., additional, Huynh, T. K., additional, Cupissol, D., additional, Berge, Y., additional, Bompas, E., additional, Emile, J., additional, Chabaud, S., additional, Perol, D., additional, and Le Cesne, A., additional

Published
2011
Full Text
View/download PDF

103. Results of randomised phase II studies comparing S16020 with methotrexate in patients with recurrent head and neck cancer

Author

UCL - MD/FSIO - Département de physiologie et pharmacologie, Pivot, X., Awada, A., Gedouin, D, Kerger, Joseph, Rolland, F, Cupissol, D, Caponigro, F, Comella, G, Lopez-Pousa, JJ, Guardiola, E, Giroux, B, Gerard, Benoît, Schneider, A, UCL - MD/FSIO - Département de physiologie et pharmacologie, Pivot, X., Awada, A., Gedouin, D, Kerger, Joseph, Rolland, F, Cupissol, D, Caponigro, F, Comella, G, Lopez-Pousa, JJ, Guardiola, E, Giroux, B, Gerard, Benoît, and Schneider, A

Abstract

Background: The purpose of this study was to carry out two randomised phase II trials of S 16020, a new olivacine derivative, tested as a single agent in patients with recurrent head and neck cancer, using methotrexate as the control arm to validate the results. Patients and methods: S 16020 at either 80 or 100 mg/m(2) was administered as a 3-h infusion every 3 weeks. Methotrexate, 40 or 50 mg/m(2), was given by bolus injection, weekly for a minimum of 6 weeks. In total, 36 patients were entered in the randomised studies (25 in an initial study, 11 in a confirmatory study) of whom 24 received S 16020 and 12 received methotrexate. Results: A scheduled interim analysis showed one patient having a non-confirmed objective response with S16020 and three patients having a confirmed objective response with methotrexate. In the methotrexate group, there were no patients with severe non-haematological toxicity. With S16020, there was a high incidence of severe non-haematological toxicities, including asthenia, oedema of the face, oedema and pain at the turnout sites and erythematous rash; consequently, both studies were stopped. Conclusions: Both studies were stopped due to the poor anticipated benefit/risk ratio for S16020, although time to progression and overall survival time were similar in both treatment arms.

Published
2003

104. Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis

Author

Dufresne, A, primary, Bertucci, F, additional, Penel, N, additional, Le Cesne, A, additional, Bui, B, additional, Tubiana-Hulin, M, additional, Ray-Coquard, I, additional, Cupissol, D, additional, Chevreau, C, additional, Perol, D, additional, Goncalves, A, additional, Jimenez, M, additional, Bringuier, P P, additional, and Blay, J Y, additional

Published
2010
Full Text
View/download PDF

105. BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients: Preliminary results of a randomized, open-label phase II study.

Author

Seiwert, T. Y., primary, Clement, P. M., additional, Cupissol, D., additional, Del Campo, J., additional, de Mont-Serrat, H., additional, Thurm, H. C., additional, Blackman, A. S., additional, and Cohen, E. E., additional

Published
2010
Full Text
View/download PDF

113. Recommandations pour la Pratique Clinique : Standards, Options et Recommandations 2005 pour la prise en charge des patients adultes atteints d’un mélanome cutané MO Texte court

Author

Négrier, S., primary, Saiag, P., additional, Guillot, B., additional, Verola, O., additional, Avril, M.-F., additional, Bailly, C., additional, Cupissol, D., additional, Dalac, S., additional, Danino, A., additional, Dreno, B., additional, Grob, J.-J., additional, Leccia, M.-T., additional, Renaud-Vilmer, C., additional, and Bosquet, L., additional

Published
2005
Full Text
View/download PDF

116. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma

Author

Mornex, F, primary, Thomas, L, additional, Mohr, P, additional, Hauschild, A, additional, Delaunay, M M, additional, Lesimple, T, additional, Tilgen, W, additional, Bui, B N, additional, Guillot, B, additional, Ulrich, J, additional, Bourdin, S, additional, Mousseau, M, additional, Cupissol, D, additional, Bonneterre, M E, additional, de Gislain, C, additional, Bensadoun, R J, additional, and Clavel, M, additional

Published
2003
Full Text
View/download PDF

117. LBA29_PR - Afatinib Versus Methotrexate (Mtx) As Second-Line Treatment for Patients with Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (Hnscc) Who Progressed After Platinum-Based Therapy: Primary Efficacy Results of Lux-Head & Neck 1, a Phase III Trial

Author

Machiels, J-P., Haddad, R.I., Fayette, J., Licitra, L.F., Tahara, M., Vermorken, J.B., Clement, P.M., Gauler, T., Cupissol, D., Grau, J.J., Guigay, J., Caponigro, F., De Castro, G., Jr, De Souza Viana, L., Keilholz, U., Del Campo, J.M., Cong, X.J., Svensson, L., Ehrnrooth, E., and Cohen, E.E.W.

Published
2014
Full Text
View/download PDF

119. Cutaneous melanoma

Author

Négrier, S, primary, Fervers, B, additional, Bailly, C, additional, Beckendorf, V, additional, Cupissol, D, additional, Doré, J F, additional, Dorval, T, additional, Garbay, J R, additional, and Vilmer, C, additional

Published
2001
Full Text
View/download PDF

125. Long term results of an adjuvant therapy with low doses IFN-??2A in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases

Author

Grab, J J, primary, Dreno, B, additional, Delaunay, M, additional, Chastang, C, additional, Cupissol, D, additional, Guillot, B, additional, Souteyrand, P, additional, Sassolas, B, additional, Cesarini, J P, additional, Lyonnet, S, additional, Lok, C, additional, Mansat, E, additional, Lacour, J P, additional, Thomas, L, additional, Beylot, M, additional, Truchetet, F, additional, de la Salmoni??re, P, additional, Chemaly, C, additional, Lorette, G, additional, Meynadier, J, additional, Thyss, R, additional, Avrii, M F, additional, Prigent, F, additional, Chevrant-Breton, J, additional, Dalac, S, additional, Fargeot, C, additional, Amblard, P, additional, Schaerrer, E, additional, Thill, L, additional, Massimini, G, additional, and Royer, P, additional

Published
1997
Full Text
View/download PDF

129. Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial†

Author

Clement, P. M., Gauler, T., Machiels, J. P., Haddad, R. I., Fayette, J., Licitra, L. F., Tahara, M., Cohen, E. E. W., Cupissol, D., Grau, J. J., Guigay, J., Caponigro, F., de Castro, G., de Souza Viana, L., Keilholz, U., del Campo, J. M., Cong, X. J., Ehrnrooth, E., and Vermorken, J. B.

Subjects
afatinib, methotrexate, HNSCC, second-line, phase III, older
Abstract

Background: In the phase III LUX-Head & Neck 1 (LHN1) trial, afatinib significantly improved progression-free survival (PFS) versus methotrexate in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients progressing on/after platinum-based therapy. This report evaluates afatinib efficacy and safety in prespecified subgroups of patients aged ≥65 and <65 years. Patients and methods Patients were randomized (2:1) to 40 mg/day oral afatinib or 40 mg/m2/week intravenous methotrexate. PFS was the primary end point; overall survival (OS) was the key secondary end point. Other end points included: objective response rate (ORR), patient-reported outcomes, tumor shrinkage, and safety. Disease control rate (DCR) was also assessed. Results: Of 483 randomized patients, 27% (83 afatinib; 45 methotrexate) were aged ≥65 years (older) and 73% (239 afatinib; 116 methotrexate) <65 years (younger) at study entry. Similar PFS benefit with afatinib versus methotrexate was observed in older {median 2.8 versus 2.3 months, hazard ratio (HR) = 0.68 [95% confidence interval (CI) 0.45–1.03], P = 0.061} and younger patients [2.6 versus 1.6 months, HR = 0.79 (0.62–1.01), P = 0.052]. In older and younger patients, the median OS with afatinib versus methotrexate was 7.3 versus 6.4 months [HR = 0.84 (0.54–1.31)] and 6.7 versus 6.2 months [HR = 0.98 (0.76–1.28)]. ORRs with afatinib versus methotrexate were 10.8% versus 6.7% and 10.0% versus 5.2%; DCRs were 53.0% versus 37.8% and 47.7% versus 38.8% in older and younger patients, respectively. In both subgroups, the most frequent treatment-related adverse events were rash/acne (73%–77%) and diarrhea (70%–80%) with afatinib, and stomatitis (43%) and fatigue (31%–34%) with methotrexate. Fewer treatment-related discontinuations were observed with afatinib (each subgroup 7% versus 16%). A trend toward improved time to deterioration of global health status, pain, and swallowing with afatinib was observed in both subgroups. Conclusions: Advancing age (≥65 years) did not adversely affect clinical outcomes or safety with afatinib versus methotrexate in second-line R/M HNSCC patients. Clinical trial registration NCT01345682 (ClinicalTrials.gov).

Published
2016
Full Text
View/download PDF

132. Is interferon al2B a good candidate for adjuvant therapy? Open study results in 54 malignant melanoma patients

Author

Cupissol, D., primary, Serrou, B., additional, Guillot, B., additional, Stoebner, A., additional, Caubel, M., additional, Viraben, C., additional, Thyss, A., additional, Drobacheff, C., additional, Bonnefoi, H., additional, Camenen, J, additional, Labeille, J., additional, Souteyrand, P., additional, Schubert, B., additional, and Maury, J. P., additional

Published
1993
Full Text
View/download PDF

136. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study.

Author

Dorval, Thierry, Négrier, Sylvie, Chevreau, Christine, Avril, Marie-Françoise, Baume, Daniel, Cupissol, Didier, Oskam, Ralph, de Peuter, Ria, Vinke, Jan, Herrera, Alain, Escudier, Bernard, Dorval, T, Négrier, S, Chevreau, C, Avril, M F, Baume, D, Cupissol, D, Oskam, R, de Peuter, R, and Vinke, J

Published
1999
Full Text
View/download PDF

140. Inhibition of dihydropyrimidine dehydrogenase by alpha-interferon: experimental data on human tumor cell lines.

Author

Milano, G, Fischel, J L, Etienne, M C, Renée, N, Formento, P, Thyss, A, Gaspard, M H, Thill, L, and Cupissol, D

Abstract

Interferons (IFNs) are very promising fluorouracil (FU) biochemical modulators. The pharmacological origin sustaining the FU-IFN synergistic interaction is not clearly understood. It was recently shown that alpha-IFN was associated with a dose-dependent decrease in FU clearance in treated patients. Dihydropyrimidine dehydrogenase (DPD) is the key regulating enzyme for FU catabolism. The effects on DPD exerted by both the IFN dose and the duration of exposure were evaluated in a panel of five human cancer cell lines. All cell lines investigated exhibited quantifiable DPD activity with inter-cell-line variability (0.118-0.318 nmol min-1 mg protein-1). A prolonged exposure to IFN (up to 5 days) was necessary to obtain a significant inhibition of DPD activity. A concentration-dependent significant decrease in DPD activity, reaching 50% of the initial activity determined for the highest IFN concentration (10(5) IU/ml), was demonstrated in all cell lines tested (5-day IFN exposure). For three cell lines, IFN potentiated the FU-induced growth inhibition in a concentration-dependent manner. Considering all cell lines and all IFN concentrations, it appears that globally, the greater the inhibition of DPD activity, the greater the FU potentiation (Spearman rank correlation on all cell lines, P = 0.011). [ABSTRACT FROM AUTHOR]

Published
1994

141. Tumor-tissue and plasma concentrations of platinum during chemotherapy of non-small-cell lung cancer patients.

Author

Pujol, Jean-Louis, Cupissol, Didier, Gestin-Boyer, Christine, Bres, Jeanine, Serrou, Bernard, Michel, François-Bernard, Pujol, J L, Cupissol, D, Gestin-Boyer, C, Bres, J, Serrou, B, and Michel, F B

Abstract

Tumor-tissue and plasma concentrations of platinum were studied prospectively in two groups of eight patients who were suffering from advanced non-small-cell lung cancer. Treatments including two different schedules of cisplatin administration (25 vs 100 mg/m2 on day 1) were compared. At 30 min after the beginning of the cisplatin infusion, blood samples and bronchoscopically obtained biopsy specimens were taken for determinations of platinum concentrations by means of flameless atomic absorption spectrophotometry. The procedure did not induce any complication. Total plasma platinum concentrations at 30 min were significantly lower (P less than 0.01) in patients receiving 25 mg/m2 (0.49 +/- 0.23 microgram Pt/ml) than in those receiving 100 mg/m2 (1.44 +/- 0.62 micrograms Pt/ml), whereas no significant difference was observed in tumor-tissue platinum concentrations (22.49 +/- 53.89 ng Pt/mg in patients receiving 25 mg/m2 vs 51.13 +/- 65.52 ng Pt/mg in those receiving 100 mg/m2). There was a weak correlation between simultaneous plasma and tumor-tissue platinum concentrations at 30 min. Tumor-tissue platinum concentrations seem to be poorly influenced by the cisplatin dose. This finding suggests a great interindividual variability of platinum tumor-diffusion properties in non-small-cell lung cancer. [ABSTRACT FROM AUTHOR]

Published
1990
Full Text
View/download PDF

142. Circulating tumour cells in head and neck cancer.

Author

Garrel, R., Cupissol, D., and Alix-Panabieres, C.

Subjects
HEAD & neck cancer, TUMORS, CANCER, THERAPEUTICS, CELLS
Abstract

Circulating tumour cells (CTC) constitute a real revolution in the field of oncology and have recently been studied prospectively for the first time in head and neck cancer by the Montpellier university hospital and Montpellier cancer institute teams. Pantel, Circulating tumor cells in head and neck carcinomas. [Extracted from the article]

Published
2020
Full Text
View/download PDF

145. A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial.

Author

Le Cesne, A., Blay, J.-Y., Cupissol, D., Italiano, A., Delcambre, C., Penel, N., Isambert, N., Chevreau, C., Bompas, E., Bertucci, F., Chaigneau, L., Piperno-Neumann, S., Salas, S., Rios, M., Guillemet, C., Bay, J.-O., Ray-Coquard, I., Haddag, L., Bonastre, J., and Kapso, R.

Subjects
*TRABECTEDIN, *LIPOSARCOMA, *LEIOMYOSARCOMA, *QUALITY of life, *DRUG efficacy
Abstract

The French Sarcoma Group assessed the efficacy, safety, and quality of life (QoL) of trabectedin versus best supportive care (BSC) in patients with advanced soft tissue sarcoma (STS). This randomized, multicenter, open-label, phase III study included adults with STS who progressed after 1-3 prior treatment lines. Patients were randomized (1 : 1) to receive trabectedin 1.5 mg/m2 every 3 weeks or BSC, stratified into L-STS (liposarcoma/leiomyosarcoma) and non-L-STS groups (other histotypes). Patients from the BSC arm were allowed to cross over to trabectedin at progression. The primary efficacy endpoint was progression-free survival (PFS) confirmed by blinded central review and analyzed in the intention-to-treat population. Between 26 January 2015 and 5 November 2015, 103 heavily pre-treated patients (60.2% with L-STS) from 16 French centers were allocated to receive trabectedin (n = 52) or BSC (n = 51). Median PFS was 3.1 months [95% confidence interval (CI) 1.8-5.9 months] in the trabectedin arm versus 1.5 months (0.9-2.6 months) in the BSC arm (hazard ratio = 0.39, 95% CI 0.24-0.64, P < 0.001) with benefits observed across almost all analyzed subgroups, but particularly in patients with L-STS (5.1 versus 1.4 months, P = 0.0001). Seven patients (13.7%) in the trabectedin arm (all with L-STS) achieved a partial response, while no objective responses were observed in the BSC arm (P = 0.004). The most common grade 3/4 adverse events were neutropenia (44.2% of patients), leukopenia (34.6%), and transaminase increase (32.7%). Health-related 30-item core European Organization for the Research and Treatment of Cancer Quality-of-Life Questionnaire evidenced no statistical differences between the arms for any domain and at any time point. After progression, 91.8% of patients crossed over from BSC to trabectedin. Trabectedin demonstrates superior disease control to BSC without impairing QoL in patients with recurrent STS of multiple histologies, with greater impact in patients with L-STS. • In adults with STS, trabectedin significantly prolonged PFS as compared to BSC. • Overall, 13.7% achieved a partial response in the trabectedin arm, while no objective response was observed in the BSC arm. • Benefits were observed across most of analyzed subgroups, but particularly in patients with liposarcoma/leiomyosarcoma. • QoL questionnaire evidenced no statistical difference between the arms for any domain or time point. • Trabectedin has superior disease control to BSC in patients with recurrent STS of multiple histologies. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results